Merck & Co. experienced a downward movement in its share price, suggesting investors may be engaging in profit-taking or re-evaluating the company’s near-term outlook. This occurred despite several positive developments in the company’s oncology pipeline.

On June 1, 2026, positive five-year follow-up data for intismeran autogene in combination with KEYTRUDA for high-risk melanoma were presented at the ASCO Annual Meeting, demonstrating a significant reduction in the risk of recurrence or death. Additionally, new data for sacituzumab tirumotecan (sac-TMT) in combination with Keytruda for first-line non-small cell lung cancer in Chinese patients also showed a clear advantage over monotherapy and was noted as a second positive readout for…